- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Alice Goodman | Authors
Minorities benefit from more sophisticated colon cancer screening
July 14, 2010
Current guidelines may be inadequate in at-risk African-American and Latino populations.
From the ONI archives: Ofatumumab turns in encouraging results in pretreated CLL
June 22, 2010
Standard therapy options are limited for patients with refractory chronic lymphocytic leukemia, with or without lymphadenopathy, and the results are generally poor. Ofatumumab (Arzerra), a novel human CD20 monoclonal antibody, could be the answer for improving outcomes in this patient population. Lead investigator William G. Wierda, MD, PhD, will share the final analysis of the results from this international study at ASH 2010.
Multigene assays influence treatment decisions in low-risk breast cancer patients
May 17, 2010
Tests carry a significant price tag, but reduction in chemotherapy use is potentially cost-saving.
Children with acute lymphoblastic leukemia gain little by participating in clinical trials
May 17, 2010
Parents and their children need to understand that advancing science does not always go hand-in-hand with a direct benefit to the patients.
Everolimus achieves ‘potent’ results in rare form of NHL
April 15, 2010
There currently are no approved therapies for Waldenström macroglobulinemia, but everolimus (Afinitor) may be the answer. A collaborative phase II study showed encouraging single-agent activity with everolimus in relapsed and/or refractory disease.
Single-shot Zevalin presents new lymphoma Rx option
March 18, 2010
Unlike conventional radiation, Yttrium-90-ibritumomab tiuxetan (Zevalin) induces cellular damage only in the targeted tumor cells and has demonstrated activity in follicular and diffuse large B-cell non-Hodgkin’s lymphoma.
Follicular lymphoma: Is watchful waiting still a treatment option in era of new and improved therapy?
March 18, 2010
In asymptomatic disease, overall survival is often the same with immediate treatment vs watch and wait. The deciding factor may be what patients are willing to tolerate.
Younger acute myelogenous leukemia patients respond favorably to anthracycline dose intensification
February 23, 2010
Induction therapy with higher daily doses of daunorubicin improved complete response and boosted overall survival in younger patients with acute myelogenous leukemia, according to results of the phase III ECOG E1900 trial.
Bendamustine Plus Rituximab Offers New Standard of Care for Treatment of NHL and Indolent Lymphoma
January 21, 2010
In a potentially practice-changing study, bendamustine plus rituximab improved PFS compared with CHOP plus rituximab as first-line therapy for indolent lymphoma.
Four-drug regimen ups response, progression-free survival in older multiple myeloma patients
January 21, 2010
More is better, at least when it comes to treatments for multiple myeloma. Studies from Spanish and Italian investigators showed that upfront use of four drugs improves durable responses and progression-free survival in elderly patients.